Novo Nordisk A/S May Spend as Much as $2 Billion on Takeovers

Oct. 30 (Bloomberg) -- Novo Nordisk A/S is earmarking as much as $2 billion for takeovers in the next 12 months as the financial crisis forces cash-strapped biotechnology companies onto the market, Chief Financial Officer Jesper Brandgaard said.